[{"id":"9f749ec0-9a4e-415b-87ef-80069ba67c42","acronym":"MA-CRC-II-018","url":"https://clinicaltrials.gov/study/NCT07478731","created_at":"2026-03-28T01:41:18.497Z","updated_at":"2026-03-28T01:41:18.497Z","phase":"Phase 2","brief_title":"Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT07478731 - MA-CRC-II-018","lead_sponsor":"Hong Qiu","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e retlirafusp alfa (SHR-1701)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 12/20/2025","start_date":" 12/20/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2026-03-17"},{"id":"e4baa55a-d5fd-4d12-b94b-469d7cf34282","acronym":"","url":"https://clinicaltrials.gov/study/NCT04950322","created_at":"2021-07-06T12:52:49.361Z","updated_at":"2024-07-02T16:35:20.325Z","phase":"Phase 3","brief_title":"A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","source_id_and_acronym":"NCT04950322","lead_sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • retlirafusp alfa (SHR-1701)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 737","initiation":"Initiation: 12/06/2021","start_date":" 12/06/2021","primary_txt":" Primary completion: 03/15/2025","primary_completion_date":" 03/15/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-02-07"},{"id":"4da35385-bc68-447a-9f55-d20c695bb000","acronym":"","url":"https://clinicaltrials.gov/study/NCT04407741","created_at":"2021-01-18T21:15:24.844Z","updated_at":"2024-07-02T16:35:26.534Z","phase":"Phase 1/2","brief_title":"Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas","source_id_and_acronym":"NCT04407741","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e retlirafusp alfa (SHR-1701) • zeprumetostat (SHR-2554)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-12"},{"id":"dd523315-933e-4b07-983a-f874fc81fa59","acronym":"","url":"https://clinicaltrials.gov/study/NCT05671822","created_at":"2023-01-05T14:58:24.565Z","updated_at":"2024-07-02T16:35:51.127Z","phase":"Phase 2","brief_title":"Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2+ Gastric Cancer","source_id_and_acronym":"NCT05671822","lead_sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • trastuzumab rezetecan (SHR-A1811) • retlirafusp alfa (SHR-1701)"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 03/14/2023","start_date":" 03/14/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2026","study_completion_date":" 07/30/2026","last_update_posted":"2023-04-07"},{"id":"6fe8f0e9-8178-43af-8474-eda668b88de5","acronym":"MULAN","url":"https://clinicaltrials.gov/study/NCT04355858","created_at":"2021-01-18T21:03:24.371Z","updated_at":"2024-07-02T16:36:06.637Z","phase":"Phase 2","brief_title":"Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer","source_id_and_acronym":"NCT04355858 - MULAN","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • everolimus • AiRuiKa (camrelizumab) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel • fulvestrant • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • retlirafusp alfa (SHR-1701) • famitinib (SHR 1020) • SHR7390 • zeprumetostat (SHR-2554) • AiRuiEn (rezvilutamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 319","initiation":"Initiation: 05/01/2020","start_date":" 05/01/2020","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2022-07-26"}]